Smriti Sharma and Vinayak Bhatia* Pages 1 - 10 ( 10 )
Drug design based on degradation-resistant, long-acting Glucagon-like peptide-1 receptor (GLP-1R) agonists for treating type 2 diabetes is attracting lot of attention. Here, the authors have examined in detail how in silico drug design is aiding in developing novel GLP-1 receptor agonist drugs. Their pharmacotherapy and adverse effects have also been summarized. After the analysis of currently available information on this topic, the authors feel that in silico method is a great auxiliary tool in almost all the experimental studies on GLP-1 receptors and is highly efficient in identifying novel drug molecules that can act as GLP-1 receptor agonists.
GLP-1, Type 2 diabetes mellitus (T2DM), GLP-1 receptor agonists, In Silico, CADDD, Molecular docking, Drug design
Department of Chemistry, Miranda House, University of Delhi, ICARE Eye Hospital and Postgraduate Institute, U.P., Noida